Zentalis Pharmaceuticals Llc

Stock Chart, Company Information, and Scan Results

$1.87(as of Aug 21, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Zentalis Pharmaceuticals Llc Company Information, Fundamentals, and Technical Indicators

Stock Price$1.87
Ticker SymbolZNTL
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees166
CountyUSA
Market Cap$118.3M

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Zentalis Pharmaceuticals Llc In Our Stock Scanner

As of Aug 22, 2025
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.